Glaxosmithkline reported GBP6.3B in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
AbbVie USD 5.31B 178M Sep/2026
Amgen USD 6.39B 169M Sep/2026
AstraZeneca USD 6.93B 362M Jun/2026
Aurora Cannabis CAD 187.54M 12.47M Jun/2026
Bausch Health Companies USD 1.59B 11M Sep/2026
Bristol-Myers Squibb USD 2.7B 33M Sep/2026
Canopy Growth CAD 107.46M 3.06M Jun/2026
Corcept Therapeutics USD 11.91M 1.28M Sep/2026
Drreddys Laboratories INR 81.18B 4.65B Sep/2026
Eli Lilly USD 18.19B 1.4B Sep/2026
GlaxoSmithKline GBP 6.28B 125M Jun/2026
Glaxosmithkline GBP 6.3B 143M Sep/2026
J&J USD 15.38B 233M Sep/2026
Merck USD 6.16B 43M Sep/2026
Novartis USD 6.1B 116M Sep/2026
Pacira USD 3.83B 3.69B Sep/2026
Perrigo USD 1.01B 50.7M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
Phibro Animal Health USD 567.14M 32.26M Sep/2026
Prestige Brands USD 179.2M 11.01M Sep/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 24.12B 620M Jun/2026
Supernus Pharmaceuticals USD 113.24M 6.22M Sep/2026
Takeda JPY 1.44T 6.17B Sep/2026
Teva Pharmaceutical Industries USD 3.17B 48M Sep/2026
Zoetis USD 2.54B 38M Sep/2026